PD-1/PD-L1 in disease
- PMID: 29260623
- DOI: 10.2217/imt-2017-0120
PD-1/PD-L1 in disease
Abstract
Aim: Expression of PD-1 on T/B cells regulates peripheral tolerance and autoimmunity. Binding of PD-1 to its ligand, PD-L1, leads to protection against self-reactivity. In contrary, tumor cells have evolved immune escape mechanisms whereby overexpression of PD-L1 induces anergy and/or apoptosis of PD-1 positive T cells by interfering with T cell receptor signal transduction. PD-L1 and PD-1 blockade using antibodies are in human clinical trials as an alternative cancer treatment modality. Areas covered: We describe the role of PD-1/PD-L1 in disease in the context of autoimmunity, neurological disorders, stroke and cancer.
Conclusion: For immunotherapy/vaccines to be successful, the expression of PD-L1/PD-1 on immune cells should be considered, and the combination of checkpoint inhibitors and vaccines may pave the way for successful outcomes to disease.
Keywords: PD-1; PD-L1; autoimmune disease; cancer; neurological disease; vaccines.
Similar articles
-
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.Hum Vaccin Immunother. 2019;15(5):1111-1122. doi: 10.1080/21645515.2019.1571892. Epub 2019 Mar 19. Hum Vaccin Immunother. 2019. PMID: 30888929 Free PMC article. Review.
-
The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.Pediatr Blood Cancer. 2015 Feb;62(2):190-197. doi: 10.1002/pbc.25284. Epub 2014 Oct 18. Pediatr Blood Cancer. 2015. PMID: 25327979 Review.
-
PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.Ann Hematol. 2018 Feb;97(2):229-237. doi: 10.1007/s00277-017-3176-6. Epub 2017 Nov 11. Ann Hematol. 2018. PMID: 29128997 Review.
-
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.Int J Clin Oncol. 2016 Jun;21(3):462-73. doi: 10.1007/s10147-016-0959-z. Epub 2016 Feb 22. Int J Clin Oncol. 2016. PMID: 26899259 Free PMC article. Review.
-
PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.Int J Mol Sci. 2017 Jun 21;18(6):1331. doi: 10.3390/ijms18061331. Int J Mol Sci. 2017. PMID: 28635644 Free PMC article. Review.
Cited by
-
Association between PD-1 and PD-L1 Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies.Cancers (Basel). 2019 Aug 10;11(8):1150. doi: 10.3390/cancers11081150. Cancers (Basel). 2019. PMID: 31405171 Free PMC article.
-
Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases.Front Pharmacol. 2021 Dec 23;12:790963. doi: 10.3389/fphar.2021.790963. eCollection 2021. Front Pharmacol. 2021. PMID: 35002724 Free PMC article. Review.
-
Regulatory mechanisms of PD-1/PD-L1 in cancers.Mol Cancer. 2024 May 18;23(1):108. doi: 10.1186/s12943-024-02023-w. Mol Cancer. 2024. PMID: 38762484 Free PMC article. Review.
-
Evaluating the Possible Association between PD-1 (Rs11568821, Rs2227981, Rs2227982) and PD-L1 (Rs4143815, Rs2890658) Polymorphisms and Susceptibility to Breast Cancer in a Sample of Southeast Iranian Women.Asian Pac J Cancer Prev. 2020 Oct 1;21(10):3115-3123. doi: 10.31557/APJCP.2020.21.10.3115. Asian Pac J Cancer Prev. 2020. PMID: 33112575 Free PMC article.
-
Decreased NSG3 enhances PD-L1 expression by Erk1/2 pathway to promote pancreatic cancer progress.Am J Cancer Res. 2021 Mar 1;11(3):916-929. eCollection 2021. Am J Cancer Res. 2021. PMID: 33791163 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials